Safety of 17D derived yellow fever vaccines

Bibliography

• Staples JE, Monath TP. Yellow fever: 100 years of discovery. JAMA 2008;300:960-2
   PubMed Web of Science ®Google Scholar
• Monath TP. Yellow fever: an update. Lancet Infect Dis 2001;1:11-20
   PubMedGoogle Scholar
• Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990;44:649-88
   PubMed Web of Science ®Google Scholar
• Yellow fever vaccine. WHO position paper. Wkly Epidemiol Rec 2003;78:349-59
   PubMedGoogle Scholar
• Available from: http://www.who.int
   Google Scholar
• Yellow fever preparedness. Lancet 2008;371:786
   Google Scholar
• Outbreak news. Yellow fever, Paraguay. Wkly Epidemiol Rec 2008;83:105
   PubMedGoogle Scholar
• Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp Immunol Microbiol Infect Dis 2004;27:319-30
   PubMed Web of Science ®Google Scholar
• Wilson ME, Chen LH, Barnett ED. Yellow fever immunizations: indications and risks. Curr Infect Dis Rep 2004;6:34-42
   PubMedGoogle Scholar
• Theiler M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 1937;65:787-800. Rev Med Virol 2000;10:6-16; discussion 13-15.
   PubMedGoogle Scholar
• Monath T. Yellow fever vaccine. Fourth edition. In: Plotkin S, Saunders WB, Vaccines. 2004. p. 1095-976
   Google Scholar
• Monath TP. Yellow fever: victor, victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am J Trop Med Hyg 1991;45:1-43
   PubMed Web of Science ®Google Scholar
• Available from: http://www.who.int/html
   Google Scholar
• Control. Global Programme for Vaccines and Immunization Expanded Programme on Immunization Division of Emerging and other Communicable Diseases Surveillance and Control: Yellow Fever-Technical Consensus Meeting. Edited by. Geneva: World Health Organization; 1998
   Google Scholar
• Assessment of yellow fever epidemic risk–a decision-making tool for preventive immunization campaigns. Wkly Epidemiol Rec 2007;82:153-60
   PubMedGoogle Scholar
• Roberts L. Infectious disease. Resurgence of yellow fever in Africa prompts a counterattack. Science 2007;316:1109
   PubMed Web of Science ®Google Scholar
• Galler R, Post PR, Santos CN, Ferreira II. Genetic variability among yellow fever virus 17D substrains. Vaccine 1998;16:1024-8
   PubMed Web of Science ®Google Scholar
• Pugachev KV, Ocran SW, Guirakhoo F, et al. Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine 2002;20:996-9
   PubMed Web of Science ®Google Scholar
• Fox JP, Lennette EH, Manso C, et al. Encephalitis in man following vaccination with 17D yellow fever virus. Am J Hyg 1942;36:117-42
   Google Scholar
• Fox JP, Penna HA. Behaviour of 17D yellow fever virus in rhesus monkeys. Relation to substrain, dose and neural or extraneural inoculation. Am J Hyg 1943;38:152-72
   Google Scholar
• United Nations Relief and Rehabilitaion Administration. UNRaRA: standards for the manufacture and control of yellow fever vaccine. Epidem Inform Bull 1945;1:365
   Google Scholar
• WHO Expert Committee on Biological Standardization. Forty-sixth report. World Health Organ Tech Rep Ser 1998;872:i-vii, 1-90
   PubMedGoogle Scholar
• Guirakhoo F, Zhang Z, Myers G, et al. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viraemia/viscerotropism for monkeys. J Virol 2004;78:9998-10008
   PubMed Web of Science ®Google Scholar
• Galler R, Freire MS, Jabor AV, Mann GF. The yellow fever 17D vaccine virus: molecular basis of viral attenuation and its use as an expression vector. Braz J Med Biol Res 1997;30:157-68
   PubMed Web of Science ®Google Scholar
• dos Santos CN, Post PR, Carvalho R, et al. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res 1995;35:35-41
   PubMed Web of Science ®Google Scholar
• Hahn CS, Dalrymple JM, Strauss JH, Rice CM. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci USA 1987;84:2019-23
   PubMed Web of Science ®Google Scholar
• Querec TD, Pulendran B. Understanding the role of innate immunity in the mechanism of action of the live attenuated yellow fever vaccine 17D. Adv Exp Med Biol 2007;590:43-53
   PubMed Web of Science ®Google Scholar
• Martins MA, Silva ML, Eloi-Santos SM, et al. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine 2008;26:1173-84
   PubMed Web of Science ®Google Scholar
• Martins MA, Silva ML, Marciano AP, et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin Exp Immunol 2007;148:90-100
   PubMed Web of Science ®Google Scholar
• Santos AP, Matos DC, Bertho AL, et al. Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. Cytokine 2008;42:152-5
   PubMed Web of Science ®Google Scholar
• Poland JD, Calisher CH, Monath TP, et al. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981;59:895-900
   PubMed Web of Science ®Google Scholar
• Expanded programme on immunization (EPI). Inclusion of yellow fever vaccine in the EPI. Wkly Epidemiol Rec 1996;71:181-5
   PubMedGoogle Scholar
• Barnett ED, Wilder-Smith A, Wilson ME. Yellow fever vaccines and international travelers. Expert Rev Vaccines 2008;7:579-87
   PubMed Web of Science ®Google Scholar
• McFarland JM, Baddour LM, Nelson JE, et al. Imported yellow fever in a United States citizen. Clin Infect Dis 1997;25:1143-7
   PubMed Web of Science ®Google Scholar
• Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002. MMWR Morb Mortal Wkly Rep 2002;51:324-5
   PubMedGoogle Scholar
• Deubel V, Huerre M, Cathomas G, et al. Molecular detection and characterization of yellow fever virus in blood and liver specimens of a non-vaccinated fatal human case. J Med Virol 1997;53:212-7
   PubMed Web of Science ®Google Scholar
• Fatal yellow fever in a traveler returning from Venezuela, 1999. MMWR Morb Mortal Wkly Rep 2000;49:303-305
   PubMedGoogle Scholar
• Van der Stuyft P, Gianella A, Pirard M, et al. Urbanisation of yellow fever in Santa Cruz, Bolivia. Lancet 1999;353:1558-62
   PubMed Web of Science ®Google Scholar
• Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002;34:1369-78
   PubMed Web of Science ®Google Scholar
• Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 1999;103:698-701
   PubMed Web of Science ®Google Scholar
• Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008;26:6077-82
   PubMed Web of Science ®Google Scholar
• Yellow fever vaccine. Recommendation of the U S Public Health Service Advisory Committee on immunization practices. Ann Intern Med 1969;71:365-7
   PubMed Web of Science ®Google Scholar
• McMahon AW, Eidex RB, Marfin AA, et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007;25:1727-34
   PubMed Web of Science ®Google Scholar
• Monath TP, Cetron MS, McCarthy K, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005;1:207-14
   PubMed Web of Science ®Google Scholar
• Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001. MMWR Morb Mortal Wkly Rep 2001;50:643-5
   PubMedGoogle Scholar
• Merlo C, Steffen R, Landis T, et al. Possible association of encephalitis and 17D yellow fever vaccination in a 29-year-old traveller. Vaccine 1993;11:691
   PubMed Web of Science ®Google Scholar
• Anonymous: fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA 1966;198:671-2
   PubMed Web of Science ®Google Scholar
• Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002;85:131-4
   PubMedGoogle Scholar
• Chan RC, Penney DJ, Little D, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001;358:121-2
   PubMed Web of Science ®Google Scholar
• Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001;358:98-104
   PubMed Web of Science ®Google Scholar
• Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001;358:91-7
   PubMed Web of Science ®Google Scholar
• Adhiyaman V, Oke A, Cefai C, et al. Effects of yellow fever vaccination. Lancet 2001;358:1907-8
   PubMed Web of Science ®Google Scholar
• Troillet N, Laurencet F. Effects of yellow fever vaccination. Lancet 2001;358:1908-9
   PubMed Web of Science ®Google Scholar
• Werfel U, Popp W. Effects of yellow fever vaccination. Lancet 2001;358:1909
   PubMed Web of Science ®Google Scholar
• Hayes EB. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 2007;101:967-71
   PubMed Web of Science ®Google Scholar
• Bae HG, Domingo C, Tenorio A, et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 2008;197:1577-84
   PubMed Web of Science ®Google Scholar
• Doblas A, Domingo C, Bae HG, et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol 2006;36:156-8
   PubMed Web of Science ®Google Scholar
• Belsher JL, Gay P, Brinton M, et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007;25:8480-5
   PubMed Web of Science ®Google Scholar
• Gerasimon G, Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J 2005;98:653-6
   PubMed Web of Science ®Google Scholar
• Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005;23:3256-63
   PubMed Web of Science ®Google Scholar
• Martin M, Weld LH, Tsai TF, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001;7:945-51
   PubMed Web of Science ®Google Scholar
• Barwick R. History of thymoma and yellow fever vaccination. Lancet 2004;364:936
   PubMed Web of Science ®Google Scholar
• Reinhardt B, Jaspert R, Niedrig M, et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998;56:159-67
   PubMed Web of Science ®Google Scholar
• Monath TP. Yellow fever vaccine. Expert Rev Vaccines 2005;4:553-74
   PubMed Web of Science ®Google Scholar
• Munoz J, Vilella A, Domingo C, et al. Yellow fever-associated viscerotropic disease in Barcelona, Spain. J Travel Med 2008;15:202-5
   PubMed Web of Science ®Google Scholar
• Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine–associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008;198:500-7
   PubMed Web of Science ®Google Scholar
• Hacker UT, Jelinek T, Erhardt S, et al. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. J Infect Dis 1998;177:774-8
   PubMed Web of Science ®Google Scholar
• Galler R, Pugachev KV, Santos CL, et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 2001;290:309-19
   PubMed Web of Science ®Google Scholar
• Engel AR, Vasconcelos PF, McArthur MA, Barrett AD. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 2006;24:2803-9
   PubMed Web of Science ®Google Scholar
• Jennings AD, Gibson CA, Miller BR, et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis 1994;169:512-8
   PubMed Web of Science ®Google Scholar
• Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell 2004;28:244-8
   PubMedGoogle Scholar
• Perelygin AA, Scherbik SV, Zhulin IB, et al. Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci USA 2002;99:9322-7
   PubMed Web of Science ®Google Scholar
• Ghosh A, Sarkar SN, Guo W, et al. Enzymatic activity of 2′-5′-oligoadenylate synthetase is impaired by specific mutations that affect oligomerization of the protein. J Biol Chem 1997;272:33220-6
   PubMed Web of Science ®Google Scholar
• Ghosh A, Desai SY, Sarkar SN, et al. Effects of mutating specific residues present near the amino terminus of 2′-5′-oligoadenylate synthetase. J Biol Chem 1997;272:15452-8
   PubMed Web of Science ®Google Scholar
• Bonnevie-Nielsen V, Heron I, Monath TP, Calisher CH. Lymphocytic 2′,5′-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol 1995;2:302-6
   PubMedGoogle Scholar
• Cavalcanti DP, Salomao MA, Lopez-Camelo J, Pessoto MA. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 2007;12:833-7
   PubMed Web of Science ®Google Scholar
• Suzano CE, Amaral E, Sato HK, Papaiordanou PM. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 2006;24:1421-6
   PubMed Web of Science ®Google Scholar
• Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. J Infect Dis 1993;168:1520-3
   PubMed Web of Science ®Google Scholar
• Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002;51:1-11; quiz CE11-14
   PubMedGoogle Scholar
• Expanded programme on immunization (EPI). Immunization schedules in the WHO African region, 1995. Wkly Epidemiol Rec 1996;71:90-4
   PubMedGoogle Scholar
• Available from: http://www.cdc/vaccines
   Google Scholar
• Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet 2004;363:2073-5
   PubMed Web of Science ®Google Scholar
• Sibailly TS, Wiktor SZ, Tsai TF, et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1997;16:1177-9
   PubMed Web of Science ®Google Scholar
• Tattevin P, Depatureaux AG, Chapplain JM, et al. Yellow fever vaccine is safe and effective in HIV-infected patients. Aids 2004;18:825-7
   PubMed Web of Science ®Google Scholar
• Gowda R, Cartwright K, Bremner JA, Green ST. Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur J Haematol 2004;72:299-301
   PubMed Web of Science ®Google Scholar
• Lutkes P, Witzke O, Philipp T, et al. Vaccinations and medical recommendations for patients traveling after organ transplantation. Dtsch Med Wochenschr 2000;125:1011-6
   PubMed Web of Science ®Google Scholar
• Bruyand M, Receveur MC, Pistone T, et al. Yellow fever vaccination in non-immunocompetent patients. Med Mal Infect 2008;38(10:524-32
   PubMed Web of Science ®Google Scholar
• Available from: www.enivd.org
   Google Scholar
• Robertson S. Yellow fever. Edited by global programme for vaccines and immunization: expanded programme on immunization: WHO; 1993. The immunological basis for immunization series
   Google Scholar
• Drouet A, Chagnon A, Valance J, et al. Meningoencephalitis after vaccination against yellow fever with the 17 D strain: 2 cases. Rev Med Interne 1993;14:257-9
   PubMed Web of Science ®Google Scholar
• From the centers for disease control and prevention. Adverse events associated with 17D-derived yellow fever vaccination–United States, 2001-2002. JAMA 2002;288:2533-5
   Web of Science ®Google Scholar
• Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004;22:2103-5
   PubMed Web of Science ®Google Scholar
• Struchiner CJ, Luz PM, Dourado I, et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 2004;132:939-46
   PubMed Web of Science ®Google Scholar
• Fitzner J, Coulibaly D, Kouadio DE, et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine 2004;23:156-62
   PubMed Web of Science ®Google Scholar
• Zhou Q, Liu DW, Shi Y, et al. Adverse effects of attenuated yellow fever vaccine with multiple organ injury–a case report. Zhonghua Yi Xue Za Zhi 2005;85:936
   PubMedGoogle Scholar
• Fernandes GC, Camacho LA, Sa Carvalho M, et al. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005. Vaccine 2007;25:3124-8
   PubMed Web of Science ®Google Scholar
• PAHO/WHO: Fatal adverse events following receipt of yellow fever vaccine produced by Bio-Manguinhos, Brazil. Edited by; 2007
   Google Scholar